HEADER BLOOD CLOTTING 21-FEB-06 2CFJ TITLE PHOSPHORYLATION OF THE CYTOPLASMIC TAIL OF TISSUE FACTOR AND ITS ROLE TITLE 2 IN MODULATING STRUCTURE AND BINDING AFFINITY COMPND MOL_ID: 1; COMPND 2 MOLECULE: TISSUE FACTOR; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: TISSUE FACTOR CYTOPLASMIC DOMAIN, RESIDUES 277-295; COMPND 5 SYNONYM: TFSP 258, TF, COAGULATION FACTOR III, THROMBOPLASTIN, CD142 COMPND 6 ANTIGEN; COMPND 7 ENGINEERED: YES; COMPND 8 OTHER_DETAILS: SER258 IS PHOSPHORYLATED SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 4 ORGANISM_COMMON: HUMAN; SOURCE 5 ORGANISM_TAXID: 9606 KEYWDS PIN1, WW DOMAIN, PHOSPHORYLATION, BLOOD COAGULATION, GLYCOPROTEIN, KEYWDS 2 LIPOPROTEIN, PALMITATE, TRANSMEMBRANE, BLOOD CLOTTING EXPDTA SOLUTION NMR NUMMDL 10 AUTHOR M.SEN,S.AGRAWAL,J.W.CRAFT,W.RUF,G.B.LEGGE REVDAT 4 02-OCT-19 2CFJ 1 REMARK LINK ATOM REVDAT 3 05-DEC-12 2CFJ 1 HEADER COMPND KEYWDS AUTHOR REVDAT 3 2 1 JRNL REMARK VERSN SEQRES REVDAT 3 3 1 MODRES HET FORMUL LINK REVDAT 3 4 1 ATOM HETATM TER CONECT REVDAT 3 5 1 MASTER REVDAT 2 24-FEB-09 2CFJ 1 VERSN REVDAT 1 20-MAR-07 2CFJ 0 JRNL AUTH M.SEN,M.HERZIK,J.W.CRAFT,A.L.CREATH,S.AGRAWAL,W.RUF, JRNL AUTH 2 G.B.LEGGE JRNL TITL SPECTROSCOPIC CHARACTERIZATION OF SUCCESSIVE PHOSPHORYLATION JRNL TITL 2 OF THE TISSUE FACTOR CYTOPLASMIC REGION. JRNL REF OPEN SPECTROSC.J. V. 3 58 2009 JRNL REFN ISSN 1874-3838 JRNL PMID 20076769 JRNL DOI 10.2174/1874383800903010058 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : AMBER 8.0 REMARK 3 AUTHORS : PONDER,J.W. REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: INITIAL NMR STRUCTURES WERE CALCULATED REMARK 3 BY DYANA, WHICH INCLUDES MODIFIED SEP RESIDUE, PHOSPHORYLATED REMARK 3 SER, CRAFT AND LEGGE, 2005, J.BIOL MOL.NMR. TOP10 ANNEALLED REMARK 3 STRUCTURES THEN FURTHER MINIMIZED VIA AMBER 8.0. REMARK 4 REMARK 4 2CFJ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 21-FEB-06. REMARK 100 THE DEPOSITION ID IS D_1290027867. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 285.0 REMARK 210 PH : 6.0 REMARK 210 IONIC STRENGTH : 0 REMARK 210 PRESSURE : 1.0 ATM REMARK 210 SAMPLE CONTENTS : 90% WATER 10% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : ROESY; NOESY; TOCSY; IP-COSY; C REMARK 210 -HSQC; N-HSQC REMARK 210 SPECTROMETER FIELD STRENGTH : 800 MHZ REMARK 210 SPECTROMETER MODEL : OTHER REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NMRPIPE, NMRVIEW, DYANA, AMBER REMARK 210 8.0, MOLMOL REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 50 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 10 REMARK 210 CONFORMERS, SELECTION CRITERIA : LOWEST POTENTIAL ENERGY REMARK 210 ENSEMBLES REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: THE SINGLE 258 PHOSPHORYLATED TFCD PEPTIDE NMR STRUCTURES REMARK 210 WERE CALCULATED USING 2D HOMONUCLEAR NMR SPECTROSCOPY METHODS. REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 INITIATES BLOOD COAGULATION BY FORMING A COMPLEX WITH REMARK 400 CIRCULATING FACTOR VII OR VIIA REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 ARG A 2 101.23 -160.53 REMARK 500 1 LYS A 3 -75.15 62.56 REMARK 500 1 VAL A 6 -55.88 -169.04 REMARK 500 1 TRP A 10 -127.91 -103.27 REMARK 500 1 GLU A 12 147.72 87.58 REMARK 500 1 ASN A 13 87.04 90.55 REMARK 500 1 SEP A 14 79.61 77.44 REMARK 500 1 ASN A 17 88.93 70.96 REMARK 500 2 LYS A 3 -68.80 -158.69 REMARK 500 2 ALA A 4 -44.25 -171.62 REMARK 500 2 SER A 9 47.75 -150.19 REMARK 500 2 TRP A 10 -126.76 -129.19 REMARK 500 2 GLU A 12 149.74 87.53 REMARK 500 2 ASN A 13 105.89 89.42 REMARK 500 2 SEP A 14 78.87 53.58 REMARK 500 2 LEU A 16 135.96 -172.99 REMARK 500 2 ASN A 17 5.37 -164.07 REMARK 500 2 VAL A 18 -46.35 -154.32 REMARK 500 3 VAL A 6 -41.02 -167.78 REMARK 500 3 GLN A 8 84.79 57.40 REMARK 500 3 LYS A 11 -38.93 -175.66 REMARK 500 3 GLU A 12 148.63 91.45 REMARK 500 3 ASN A 13 85.17 90.46 REMARK 500 3 SEP A 14 79.17 77.12 REMARK 500 3 ASN A 17 -1.73 -168.70 REMARK 500 3 VAL A 18 -42.40 -150.55 REMARK 500 4 SER A 9 22.49 -75.73 REMARK 500 4 TRP A 10 -63.67 -91.95 REMARK 500 4 LYS A 11 -38.25 -160.66 REMARK 500 4 GLU A 12 146.27 92.99 REMARK 500 4 ASN A 13 85.92 93.67 REMARK 500 4 SEP A 14 79.83 74.25 REMARK 500 4 LEU A 16 119.91 69.09 REMARK 500 4 VAL A 18 -50.21 -152.97 REMARK 500 5 VAL A 6 -52.09 -143.38 REMARK 500 5 GLN A 8 18.39 -162.04 REMARK 500 5 TRP A 10 -61.92 -120.12 REMARK 500 5 LYS A 11 -38.03 -162.17 REMARK 500 5 GLU A 12 147.20 91.84 REMARK 500 5 ASN A 13 81.98 93.74 REMARK 500 5 SEP A 14 81.43 77.57 REMARK 500 5 LEU A 16 -102.27 48.46 REMARK 500 6 ARG A 2 159.56 66.89 REMARK 500 6 ALA A 4 -45.09 178.77 REMARK 500 6 GLN A 8 76.96 162.66 REMARK 500 6 SER A 9 16.12 -149.80 REMARK 500 6 LYS A 11 -37.60 151.18 REMARK 500 6 GLU A 12 151.88 82.60 REMARK 500 6 ASN A 13 90.30 83.91 REMARK 500 6 SEP A 14 75.91 79.39 REMARK 500 REMARK 500 THIS ENTRY HAS 85 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AHW RELATED DB: PDB REMARK 900 A COMPLEX OF EXTRACELLULAR DOMAIN OF TISSUE FACTOR WITH AN REMARK 900 INHIBITORY FAB (5G9) REMARK 900 RELATED ID: 1BOY RELATED DB: PDB REMARK 900 EXTRACELLULAR REGION OF HUMAN TISSUE FACTOR REMARK 900 RELATED ID: 1DAN RELATED DB: PDB REMARK 900 COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR REMARK 900 VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR REMARK 900 RELATED ID: 1FAK RELATED DB: PDB REMARK 900 HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA REMARK 900 INHIBITED WITH A BPTI-MUTANT REMARK 900 RELATED ID: 1J9C RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX REMARK 900 RELATED ID: 1JPS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF TISSUE FACTOR IN COMPLEX WITHHUMANIZED FAB REMARK 900 D3H44 REMARK 900 RELATED ID: 1NL8 RELATED DB: PDB REMARK 900 THEORETICAL MODEL OF THE TISSUE FACTOR/ FACTOR VIIA/FACTORXA COMPLEX REMARK 900 RELATED ID: 1O5D RELATED DB: PDB REMARK 900 DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTSAT THE REMARK 900 S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190UPA) REMARK 900 RELATED ID: 1TFH RELATED DB: PDB REMARK 900 EXTRACELLULAR DOMAIN OF HUMAN TISSUE FACTOR REMARK 900 RELATED ID: 1UJ3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A HUMANIZED FAB FRAGMENT OF ANTI-TISSUE-FACTOR REMARK 900 ANTIBODY IN COMPLEX WITH TISSUE FACTOR REMARK 900 RELATED ID: 1W0Y RELATED DB: PDB REMARK 900 TF7A_3771 COMPLEX REMARK 900 RELATED ID: 1W2K RELATED DB: PDB REMARK 900 TF7A_4380 COMPLEX REMARK 900 RELATED ID: 1WQV RELATED DB: PDB REMARK 900 HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITHPROPYLSULFONAMIDE-D- REMARK 900 THR-MET-P- AMINOBENZAMIDINE REMARK 900 RELATED ID: 1WSS RELATED DB: PDB REMARK 900 HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPRIDMIMETIC REMARK 900 INHIBITOR THAT HAS TWO CHARGE GROUPS IN P2 AND P4 REMARK 900 RELATED ID: 1WTG RELATED DB: PDB REMARK 900 HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITHETHYLSULFONAMIDE-D- REMARK 900 BIPHENYLALANINE-GLN-P- AMINOBENZAMIDINE REMARK 900 RELATED ID: 1WUN RELATED DB: PDB REMARK 900 HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITHETHYLSULFONAMIDE-D- REMARK 900 TRP-GLN-P- AMINOBENZAMIDINE REMARK 900 RELATED ID: 1WV7 RELATED DB: PDB REMARK 900 HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITHETHYLSULFONAMIDE-D-5- REMARK 900 PROPOXY-TRP-GLN-P- AMINOBENZAMIDINE REMARK 900 RELATED ID: 1Z6J RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTORVIIA/TISSUE FACTOR/ REMARK 900 PYRAZINONE INHIBITOR REMARK 900 RELATED ID: 2B7D RELATED DB: PDB REMARK 900 FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION, REMARK 900 PRECLINICALPHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN REMARK 900 ABABOON THROMBOSIS MODEL REMARK 900 RELATED ID: 2C4F RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF FACTOR VII.STF COMPLEXED WITH PD0297121 REMARK 900 RELATED ID: 2CEF RELATED DB: PDB REMARK 900 PHOSPHORYLATION OF THE CYTOPLASMIC TAIL OF TISSUE FACTOR AND ITS REMARK 900 ROLE IN MODULATING STRUCTURE AND BINDING AFFINITY REMARK 900 RELATED ID: 2CEH RELATED DB: PDB REMARK 900 PHOSPHORYLATION OF THE CYTOPLASMIC TAIL OF TISSUE FACTOR AND ITS REMARK 900 ROLE IN MODULATING STRUCTURE AND BINDING AFFINITY REMARK 900 RELATED ID: 2CEZ RELATED DB: PDB REMARK 900 PHOSPHORYLATION OF THE CYTOPLASMIC TAIL OF TISSUE FACTOR AND ITS REMARK 900 ROLE IN MODULATING STRUCTURE AND BINDING AFFINITY REMARK 900 RELATED ID: 2HFT RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF HUMAN TISSUE REMARK 900 FACTOR AT 1.7 ANGSTROMS RESOLUTION REMARK 999 REMARK 999 SEQUENCE REMARK 999 CYTOPLASMIC DOMAIN OF TISSUE FACTOR, WHICH IS REMARK 999 PHOSPHORYLATED AT SER258 DBREF 2CFJ A 1 19 UNP P13726 TF_HUMAN 277 295 SEQRES 1 A 19 CYS ARG LYS ALA GLY VAL GLY GLN SER TRP LYS GLU ASN SEQRES 2 A 19 SEP PRO LEU ASN VAL SER MODRES 2CFJ SEP A 14 SER PHOSPHOSERINE HET SEP A 14 13 HETNAM SEP PHOSPHOSERINE HETSYN SEP PHOSPHONOSERINE FORMUL 1 SEP C3 H8 N O6 P LINK N SEP A 14 C ASN A 13 1555 1555 1.35 LINK C SEP A 14 N PRO A 15 1555 1555 1.36 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL MASTER 215 0 1 0 0 0 0 6 0 0 0 2 END